// App-Quantinova.ai

925TiP : A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy

Researchers

Presenter

  • T.K.Choueiri

Principal Investigators

  • C.Porta

  • C.Suarez Rodriguez

  • R.Alter

  • P.Czaykowski

  • I.Duran

  • M.Gross-Goupil

  • E.Kalinka-Warzocha

  • B.Melichar

  • C.Patel

  • R.Neuwirth

  • A.Enke

  • F.Zohren

  • T.Powles

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy

  • Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain

  • Head and Neck & Urologic Oncology, Hackensack University Medical Center, Hackensack, NJ, USA

  • Medical Oncology and Haematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada

  • Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain

  • Department of Medical Oncology, CHU Bordeaux Hopital St. Andre, Bordeaux, France

  • Clinic of Oncologic Surgery and Breast Cancer, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland

  • Medical Oncology, Lekarska fakulta Univerzity Palackeho a Fakultní nemocnice, Olomouc, Czech Republic

  • Quantitative Clinical Pharmacology, Millennium Pharmaceuticals Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

  • Quantitative Clinical Pharmacology, Millennium Pharmaceuticals Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

  • Quantitative Clinical Pharmacology, Millennium Pharmaceuticals Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

  • Oncology, St. Bartholomew's Hospital, London, UK

Locations

  • United States

  • Italy

  • Spain

  • Canada

  • France

  • Poland

  • Czech Republic

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Everolimus

  • Methadone hydrochloride

  • Sapanisertib

  • Serabelisib

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved